An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Rucaparib (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Sarcoma; Squamous cell cancer; Uterine cancer
- Focus Therapeutic Use
- Acronyms EndoBARR
- 29 Jul 2019 Status changed from not yet recruiting to recruiting.
- 22 May 2019 Planned End Date changed from 28 Feb 2026 to 28 Jun 2026.
- 22 May 2019 Planned primary completion date changed from 28 Feb 2021 to 28 Jun 2021.